By Donna Loyle, communications specialist, LIMR
March is Colorectal Cancer Awareness Month, which makes this an ideal time to spotlight trial #S1613, ongoing at all Main Line Health acute care hospitals.
This trial is for patients who’ve been diagnosed with locally advanced or metastatic HER2/Neu colorectal cancer and whose tumors cannot be surgically removed.
Participants are grouped into two treatment arms:
- Those in Arm 1 receive the chemotherapy drug Herceptin® (trastuzumab) IV and the monoclonal antibody pertuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- Those in Arm 2 receive the monoclonal antibody cetuximab IV and the drug irinotecan hydrochloride IV on day 1. Courses repeat every 14 days. Patients with documented disease progression may optionally cross over to Arm I.
Patients must be willing to undergo follow-up care for up to three years. Other inclusion/exclusion criteria may apply.
The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more information, visit https://www.mainlinehealth.org/research/clinical-trials/s1613